Skip to content

PolitiKit

Lobbying by CANADIAN CANCER SOCIETY: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.

← Lobbying

Organization

CANADIAN CANCER SOCIETY

Meetings this Parliament
162
With MPs
92
Since Nov 2021
511
Active registrations
1

Most recent reported meeting: Sep 29, 2026.

Registrations in effect

In-house (organization) In effect since Jun 12, 2026 Receives government funding

Filed by Andrea Seale, Chief Executive Officer

Lobbyists

  • Andrea Seale · Chief Executive Officer
  • Angeline Webb · Senior Public Policy Advisor (Alberta)
  • Brandon Purcell · Advocacy Manager, Prevention
  • Charles Aruliah · Manager, Advocacy
  • Daniel Nowoselski · Senior Advocacy Manager
  • David Raynaud · Gestionnaire – Défense de l’intérêt public
  • Dylan Buskermolen · Advocacy Specialist
  • Elizabeth Holmes · Health Policy Analyst, Mission (National)
  • Fernanda Martins · Sr. Advocacy Coordinator
  • Heather Mulligan · Advocacy Manager, Atlantic Canada
  • Helena Sonea · Senior Manager, Advocacy
  • Hillary Buchan-Terrell · Advocacy Manager Former public office holder

    Formerly Legislative Assistant, Office of Anita Vandenbeld, MP for Ottawa West-Nepean, House of Commons (2015–2016)

  • Jane Parsons · Regional Executive Director - Atlantic
  • Julie Brown · Advocacy Specialist
  • Lana Sommerville · Advocacy Manager, Atlantic
  • Laura Orsini · Advocacy Specialist
  • Riaz Kara · Executive Vice President, Research and Advocacy Former public office holder

    Formerly Vice President & Director General, Housing Policy & Partnerships, Housing Policy & Partnerships, Canadian Mortgage and Housing Corporation & Department of Housing, Infrastructure and Communities Canada (2022–2024)

    Formerly Executive Director & acting Director General - Federal Labour Program, Labour Program, Employment and Social Development Canada (2017–2022)

    Formerly Director, Business and Client Service Policy, Business & Client Service Policy, Public Works and Government Services Canada (2015–2017)

  • Rob Cunningham · Senior Policy Analyst(National) Former public office holder

    Formerly Correspondence Assistant (summer student), Office of the Leader of the Opposition, House of Commons (1986–1986)

    Formerly Correspondence Assistant (summer student), Office of the Leader of the Opposition, House of Commons (1985–1985)

  • Sandra Krueckl · EVP, Mission, Cancer Information and Support Services
  • Sara Oates · Executive Vice President, Finance and Operations
  • Stephen Piazza · Director, Advocacy

Institutions they may lobby: Agriculture and Agri-Food Canada (AAFC), Canada Border Services Agency (CBSA), Canada Revenue Agency (CRA), Canadian Centre for Occupational Health and Safety (CCOHS), Canadian Institutes of Health Research (CIHR), Canadian Nuclear Safety Commission (CNSC), Crown-Indigenous Relations and Northern Affairs Canada (CIRNAC), Employment and Social Development Canada (ESDC), Environment and Climate Change Canada (ECCC), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Immigration, Refugees and Citizenship Canada (IRCC), Indigenous Services Canada (ISC), Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), International Development Research Centre (IDRC), Justice Canada (JC), National Defence (DND), National Research Council (NRC), Natural Sciences and Engineering Research Council (NSERC), Office of the Commissioner of Lobbying (OCL), Office of the Privacy Commissioner of Canada (OPC), Parks Canada (PC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Public Safety Canada (PS), Royal Canadian Mounted Police (RCMP), Senate of Canada, Service Canada (ServCan), Social Sciences and Humanities Research Council (SSHRC), Statistics Canada (StatCan), Treasury Board Of Canada Secretariat (TBS), Women and Gender Equality (WAGE)

What they're lobbying on (39)
  • International trade regarding tobacco control, alcohol, products containing carcinogens and products associated with cancer.
  • Internal trade regarding tobacco control, alcohol, products containing carcinogens and products associated with cancer.
  • Funding for programs to be operated by the Canadian Cancer Society to advance cancer control.
  • Canadian Partnership Against Cancer, as it relates to continued federal funding for the cancer control strategy
  • Canada Health Transfer and health system bilateral funding agreements intended for provinces/territories to support the delivery of healthcare services
  • Framework Convention on Tobacco Control, including protocols, guidelines and implementation
  • Tobacco and Vaping Products Act, as it relates to regulations, implementation and enforcement
  • Non-Smokers' Health Act including implementation and enforcement
  • Food and Drugs Act and regulations, as it relates to nciotine replacement products
  • Federal Tobacco Control Strategy, including all matters related to tobacco control
  • Taxation, revenue measures, controlled products regulations, including implementation, for alcohol, tobacco control, products containing carcinogens and products associated with cancer.
  • Communication regarding alcohol consumption guidance.
  • Food and Drugs Act and regulations, as it relates to alcohol warning labels
  • Food and Drugs Act and regulations, as it relates to restricting the advertising to children of foods high in sodium, sugars and saturated fat.
  • Healthy Living - Supporting initiatives, legislation, regulation, policies, and programs that prevent cancer or improve the social determinants of health
  • Adoption of HPV testing and increasing HPV vaccination rates
  • Sustainable funding of the National Advisory Committee on Preventive Health Services to ensure timely, up?to?date cancer screening guidelines
  • Equitable and timely access to cancer screening.
  • Measures and funding related to the charitable sector generally
  • Equitable access to care along the full cancer continuum for First Nations, Inuit and Métis communities
  • Employment Insurance special benefit programs, including the sickness benefit and compassionate care benefit
  • Canada Labour Code and Employment Insurance Act, as it relates to job-protected leave, employment insurance special benefits, return to work policies, and human rights protections for people affected by cancer
  • Access to information and support to make decisions regarding end-of-life care, including Medical Assistance In Dying
  • Supports for mental health during people's cancer journeys
  • Implementation and funding of the National Grief Action Plan as part of the government's work on palliative care and mental health
  • Canada Health Act as it relates to access to care, including long-term, home, and palliative care
  • National Caregiving Strategy
  • Financial supports for caregivers, including the Canada Caregiver Credit
  • Implementation of the Framework on Palliative Care in Canada and integration of a palliative approach to care in our health system, including national standards and data, care provider training, research, and implementation of the National Grief Action Plan and distinctions?based frameworks for First Nations, Inuit and Métis people
  • Setting and measuring pan-Canadian wait time benchmarks and targets and measures to address them, including addressing healthcare shortages, increased and sustainable funding for care, infrastructure and equipment, targeted strategic funding to PTs for workforce shortages, particularly in rural and remote communities.
  • Sustained core funding for federal research agencies, improved coverage of indirect research costs, Canadian research sovereignty, strengthening capacity and the economic benefits of domestic research, research commercialization.
  • Increasing access to care including models of care, removing barriers to care, particularly for underserved communities, using innovative approaches to improve access to care including AI to improve timely diagnosis and treatment.
  • Issues related to the healthcare workforce including efforts to coordinate and plan for workforce needs, health workforce data, the recruiting, education, training and retaining of healthcare professionals, attracting a skilled workforce including licensing and credential recognition, supportive work environments for healthcare workers, and strategic funding to address healthcare workforce shortages to improve access to care.
  • Issues related to health and cancer data including the priorities of the pan-Canadian Cancer Data Strategy, data governance and stewardship, how health data is collected, linked and used, addressing gaps in health data, health data interoperability, data issues related to health care system planning, cancer registries, benchmarks and reporting.
  • Effective post-approval pathways for medications and treatments, including health technology assessments, pricing negotiations, and public reimbursement for medications
  • Access to medication - expanding the range of medications covered by various insurance plans, and the number of Canadians able to access and afford medication.
  • Access to oncofertility treatments and support for people with cancer
  • Travel and accommodation programs to access diagnostics, treatment, and care for people in rural, remote and northern communities with cancer
  • Approvals process for the launch of clinical trials in Canada including regulation, funding, the creation of intellectual property and commercialization in Canada for the purpose of pharmaceutical sovereignty, economic development and scientific innovation.

Registration 932742-243-96. Look it up in the official Registry

Reported meetings

Spreadsheet

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.